Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys to Annotate Incyte s Protein Sequences

SAN FRANCISCO, April 25 - Accelrys will functionally annotate 10,000 protein sequences for Incyte, the companies announced Thursday.

 

The deal calls for Accelrys to use its GeneAtlas application to annotate selected sequences from Incyte's collection of rarely expressed human genes. The 3D annotations will be delivered to Incyte along with Accelrys' Discovery Studio data mining software to enable viewing the annotations and structural models, the companies said.

 

Financial details of the agreement were not disclosed.

 

"Incyte has an appreciable number of proprietary gene sequences for which little is known about the possible functions of their encoded protein," Robert Stein, Incyte's president and chief scientific officer, said in a statement. "Accelrys' high throughput technologies for predicting protein structure and recognizing similarities to other proteins of known function should be very useful in gaining a functional perspective on many of Incyte's proprietary gene sequences."

 

Accelrys is a wholly-owned subsidiary of Pharmacopeia.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.